COMPANY PROFILE

Aadi Bioscience

Clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers

Los Angeles, United StatesFounded 2011Biotech & Life Sciences

Valuation $188M Market cap · 2026

Revenue $7.1M Latest reported FY

About Aadi Bioscience

Aadi Bioscience, Inc. is a privately held biopharmaceutical company that specializes in developing and commercializing innovative treatments for diseases driven by the mTOR pathway, a key cellular signaling pathway involved in cell growth and metabolism. The company's flagship product is nab-sirolimus (ABI 009), a formulation of sirolimus bound to albumin nanoparticles designed for injectable suspension. This product is currently being developed for the treatment of advanced malignant PEComa (perivascular epithelioid cell tumor), a rare and aggressive form of cancer.

Aadi Bioscience operates in the biopharmaceutical market, focusing on both rare diseases and conditions with significant unmet medical needs. Their primary clients include healthcare providers, hospitals, and specialty clinics that treat patients with complex and treatment-resistant conditions. The company is also involved in clinical trials aimed at expanding the use of nab-sirolimus for other indications, such as treatment-resistant epilepsy.

The business model of Aadi Bioscience revolves around the development, regulatory approval, and commercialization of their proprietary drug formulations. They generate revenue through the sale of their approved drugs to healthcare institutions and potentially through partnerships or licensing agreements with larger pharmaceutical companies. By focusing on niche markets with high unmet needs, Aadi aims to secure orphan drug designations, which can provide market exclusivity and other financial incentives.

In summary, Aadi Bioscience is a forward-thinking biopharmaceutical company dedicated to bringing new hope to patients with rare and challenging diseases through innovative drug formulations and rigorous clinical research.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2011
Headquarters: Los Angeles, United States
Listing: IPO 2017
Employees: 54
Open positions: 2
Dealroom signal: 65.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Aug 2021
Capital deployed: —
Preferred round: MERGER
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	May 2026	$88M	—	Acuta Capital Partners · Avoro Capital Advisors · StemPoint Capital · Invus	↗
POST IPO EQUITYOther financing	Dec 2024	$100M	—	Ally Bridge Group · KVP Capital · Tae Han · Invus	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$7.1M	0%	−$61M	-849.6%
2025	$7.1M	-72.5%	−$61M	-849.6%
2024	$26M	+6.7%	−$61M	-233.6%
2023	$24M	+60.1%	−$65M	-268.4%
2022	$15M	+1421.6%	−$57M	-371.7%
2021	$1M	-92.9%	−$35M	-3546.3%
2020	$14M	—	−$2.7M	-18.9%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Aadi Bioscience website traffic

Latest recorded traffic for Aadi Bioscience is 5.3K monthly website visits, up 23.3% over the last three months. Aadi Bioscience's team declined 27% over the past year.

Latest monthly visits5.3K 3-month web change+23.3% 1-year team growth-27%

Monthly website visitsJan 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Legal Operations ManagerSunset Boulevard, 90272 Los Angeles, California, United States · Legal · Jul 28, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBeijing Jinlan Gene TechnologyAAV vector-based gene therapy for rare diseases	China	Operational	1	$44M	$138M
INinspirebiotx.comInspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform.Â â	Toronto, Canada	Operational
BCBTB Drug Development Research CenterA drug discovery research center that aims to contribute to reducing illness and saving lives	Kyoto, Japan	Operational
1T1E TherapeuticsFocuses on developing oligonucleotide therapeutics to treat various diseases	Rehovot, Israel	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
RPRectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases	Cambridge, United States	Operational
RBRemeGen BiosciencesBiologics for autoimmune, oncology, and ophthalmic diseases	South San Francisco, United States	Operational